Add Yahoo as a preferred source to see more of our stories on Google. Getty Images Raise your hand if you’ve got some drama happening in your underarms. If you often get pimples, blackheads, or larger ...

Hidradenitis suppurativa is a skin condition that presents with the formation of abscesses in specific areas of the body, which may be very painful and rupture to leak pus. The area usually heals with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Bimekizumab for the treatment of moderate to severe ...

Authors outline treatment strategies for hidradenitis suppurativa with a focus on diet and lifestyle management for all stages of this disorder. Hidradenitis suppurativa (HS) is a chronic inflammatory ...

If you're experiencing painful bumps or lesions forming under the skin, but it feels or looks different from a typical breakout, it could be a sign of hidradenitis suppurativa. This chronic ...

Panelists discuss the challenges of timely diagnosis and comprehensive management of hidradenitis suppurativa, emphasizing the need for early recognition, multidisciplinary care, and empathy-centered ...

SAN DIEGO -- An investigational Bruton's tyrosine kinase (BTK) inhibitor significantly improved hidradenitis suppurativa (HS) disease status in a randomized, placebo-controlled trial reported here.

AbbVie has announced that the first patient has been dosed in a late-stage study of its selective JAK inhibitor, Rinvoq (upadacitinib), in adults and adolescents with moderate-to-severe hidradenitis ...

First Phase 2 trial in hidradenitis suppurativa using the higher clinical response level of HiSCR75 as the primary endpoint Trial evaluates sonelokimab, an investigational Nanobody ® with an ...

Dublin, April 13, 2023 (GLOBE NEWSWIRE) -- The "Global Hidradenitis Suppurativa Market: Analysis By Patients, By Drugs (Povorcitinib, Bimekizumab, Sonelokimab), By Region Size (The US, Europe, Rest of ...

- Statistically significant results for primary endpoints in both STOP-HS1 and STOP-HS2 Phase 3 studies for both doses tested - Favorable safety profile, with no safety concerns - Data will support ...